An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim resultsVignesh T. Packiam, Gary D. Steinberg, Benjamin Fand et al.|Urologic Oncology Seminars and Original Investigations|2017Cited by 250
MP13-19 A PHASE II/III TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-REFRACTORY NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)Vignesh T. Packiam, Gary D. Steinberg, Alexa Campanile et al.|The Journal of Urology|2016Cited by 9